

	1 Month	3 Month	YTD	1 Year	3 Year	5 Year	Inception
BIVIX (as of 10/31/24)	0.40	-1.85	-11.34	-10.46	21.23	23.56	18.55
S&P 1500 Index	-0.94	3.30	20.12	37.54	8.69	14.90	13.66
Morningstar Cat. Avg.	-0.92	0.98	10.09	17.95	4.34	6.43	5.25
BIVIX (as of 9/30/24)	-2.13	0.35	-11.70	-9.82	20.54	23.52	18.72

Performance data quoted represents past performance; past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Current performance of the fund may be lower or higher than the performance quoted. To obtain performance data current to the most recent month-end, please call 1-855-466-3406. ****Morningstar Cat. Avg.** is the Morningstar Long/Short Equity category average.

Returns over one year are annualized and include the reinvestment of dividends and income. The fund imposes a 1.00% redemption fee on shares sold within 60 days. All data presented is as of 10/31/24, unless otherwise indicated. Fund inception: 6/19/17. Total operating fund expenses as of 3/1/24 for Class I shares: 3.08% (gross expense ratio), 2.23% (expense cap). See page 4 for additional information.


MONTHLY FUND REVIEW

The Invenomic Fund returned 0.40% for October compared to -0.94% for the S&P 1500 Index and -0.92% for the Morningstar Long/Short Equity category average. The long portfolio detracted 1.23% and the short portfolio contributed 1.52% during the month, on a gross basis. The portfolio averaged 110.1% long and -93.1% short, resulting in average net exposure of 17.0% and average gross exposure of 203.2%. The portfolio has 186 long and 136 short positions as of month-end.

MONTHLY COMMENTARY

Equity markets entered October with strong performance before selling off sharply into the end of the month. The Russell 2000 Index fell 1.44% while the Russell 1000 Value/Growth Index dropped 0.93%. Momentum continued to push higher during the month, with the Bloomberg US Pure Momentum Index up 1.43%, recording its third strongest month of the year. Despite these headwinds, the portfolio generated gains during October primarily due to the short portfolio.

The top 10 contributors in the short book collectively added 240 basis points of performance, on a gross basis, while the top 10 long positions collectively detracted 151 basis points. The biggest contributor was a long position that added 51 basis points, and the biggest detractor was a short position that cost 38 basis points, both on a gross basis. Gains and losses in our portfolio continue to be widespread, consistent with the diversification in our portfolio.



Source: Bloomberg, Invenomic.

As we look across equity markets, we continue to find valuations that are historically stretched. The chart above shows the 1-Year Forward Price-to-Sales ratio of the S&P 500 Index. The multiple is currently at levels last seen at the peak of the COVID bubble, and we are considerably higher than the peak of the dot-com bubble in early 2000. While this is one measure of extreme market valuation, we are seeing this across other multiples in the market. Though we love the names in our long portfolio, we are finding the opportunities on the short side to be amongst the most compelling we have seen. We have identified many companies where we believe their stock price has completely disconnected from their future earnings. As a result, our net exposure remains at the low end of our historical range, standing at 16.6% as of month-end.

At the time of this writing, the United States Presidential election has come and gone. We will opine on the outcome more next month. Coming into the election we did not make any material changes to the portfolio, as we are not in the business of predicting the outcome of elections. Our portfolio is constructed on a name-by-name basis rather than from a top-down point of view. If we believe the outcome of the election will present a risk or opportunity, we will make the adjustments accordingly. We continue to follow our process which has served us well over time.

If you have any questions, please do not hesitate to reach out.

Investors should carefully consider the investment objectives, risks, charges, and expenses of the Invenomic Fund. This and other important information about the Invenomic Fund is contained in the prospectus, which can be obtained at invenomic.com or by calling 1-855-466-3406. The prospectus should be read carefully before investing.

The Invenomic Fund is distributed by Northern Lights Distributors LLC, member FINRA/SIPC. Invenomic Capital Management is not affiliated with Northern Lights Distributors, LLC. To obtain performance as of the latest month-end, please call 1-855-466-3406.

Economic conditions remain highly uncertain. There is no assurance these opinions or forecasts will come to pass.

Important Risk Information: Mutual fund investing involves risk. Principal loss is possible. The Fund may use derivatives, including options, which may not perform as anticipated by the Adviser, may not be able to be closed out at a favorable time or price, or may increase the Fund's volatility. A counterparty's inability to fulfill its obligation may result in financial loss to the Fund. Increases and decreases in the value of the Fund's portfolio may be magnified when the Fund uses leverage.

The fund may make short sales of securities, which involves the risk that losses may exceed the original amount invested. Investments in debt securities typically decrease when interest rates rise. This risk is usually greater for longer-term debt securities. Investments in lower rated and non-rated securities present a greater risk of loss to principal and interest than higher-rated securities. Investing in foreign securities exposes investors to economic, political and market risks, and fluctuations in foreign currencies. The fund may invest in the securities of small and medium sized companies. Small and medium company investing subjects investors to additional risks, including security price volatility and less liquidity than investing in larger companies.

Fund expenses listed are as of 3/1/2024. Total Other Expenses includes 0.02% in recouped management fees in accordance with the operating expense limitation agreement. between Invenomic Capital Management LP (the "Adviser") and the Fund. Pursuant to the agreement, the Adviser has agreed to waive its fees and/or absorb expenses of the Fund to ensure that Total Annual Fund Operating Expenses (excluding any front-end or contingent deferred sales loads, brokerage fees and commissions, acquired fund fees and expenses, borrowing costs (such as interest and dividend expense on securities sold short), taxes and extraordinary or non-recurring expenses, including, but not limited to, litigation) for the Fund do not exceed 2.23%, 2.48% and 1.98% of the Fund's average net assets, for Institutional Class, Investor Class shares and Super Institutional Class, respectively, through February 28, 2025. The Adviser is permitted to receive reimbursement from the Fund for fees it waived and Fund expenses it paid, subject to the limitation that: (1) the reimbursement for fees and expenses will be made only if payable within three years from the date the fees and expenses were initially waived or reimbursed; and (2) the reimbursement may not be made if it would cause the expense limitation in effect at the time of the waiver or currently in effect, whichever is lower, to be exceeded. This operating expense limitation agreement can be terminated only by, or with the consent of, the Board of Trustees.

The indices shown are for informational purposes only, are not reflective of any investment, nor are they professionally managed. As it is not possible to invest in the indices, the data shown does not reflect or compare features of an actual investment, such as its objectives costs and expenses, liquidity, safety, guarantees or insurance fluctuation of principal or return, or tax features. There is no guarantee that any investment strategy will achieve its objectives, generate profits, or avoid losses.

The investment objective of the Invenomic Fund is to seek long term capital appreciation.

The S&P 1500 combines three leading indices, the S&P 500, the S&P MidCap 400, and the S&P SmallCap 600, to cover approximately 90% of U.S. market capitalization. The Morningstar Long-Short Equity Category is an average monthly return of all funds in the Morningstar Long-Short Equity Category, including the Fund. The category contains a universe of funds with similar investment objectives and investment style, as defined by Morningstar. The S&P 500 Index is a market-capitalization-weighted index of 500 leading publicly traded companies in the U.S. Mega cap is a designation for the largest companies in the investment universe as measured by market capitalization. While the exact thresholds change with market conditions, mega cap generally refers to companies with a market capitalization above \$200 billion. The Nasdaq Composite Index is a market capitalization-weighted index of more than 3,700 stocks listed on the Nasdaq stock exchange. The Russell 2000 Index is a subset of the Russell 3000® Index representing approximately 10% of the total market capitalization of that index. It includes approximately 2,000 of the smallest securities based on a combination of their market cap and current index membership. The Russell 1000 Value/Growth Index measures the relative performance of a combination of their component indexes, the Russell 1000 Value Index and the Russell 1000 Growth Index and a cash component. The Russell 1000 Value/Growth Index represents a positive weighting on the Russell 1000 Value Index and a negative weighting on the Russell 1000 Growth Index. PMOMENUS (Bloomberg Pure US Momentum Portfolio) represents the return of Momentum factor from PORT <GO> US Equity model in Bloomberg. This factor separates stocks based on their 1-year price performance. Long exposure is the percentage of dollar capital invested in the long book. Short exposure is the percentage of dollar capital in the short book. Net exposure is the long exposure minus short exposure. Gross exposure is the long exposure plus short exposure. The forward price-to-sales (P/S) ratio is calculated by dividing the current stock price by the expected sales per share for the next period. Performance of the indices and Morningstar Category Average is generated on the 1st business day of the month.

This commentary contains forward looking statements that are meant to represent the economy as of the date this is written and not intended to represent the fund. Due to uncertainties and risks associated with the markets in general, the views expressed here may not occur and are subject to change at any time.